ET-01 in Subjects With Lateral Canthal Lines, LCL-208

Completed · Phase 2

Conditions studied: Lateral Canthal Lines, Crow's Feet

In brief

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Key facts

Study ID: NCT03839693
Run by: Eirion Therapeutics Inc.
People needed: 75
Starts: 2018-10-16
Expected to finish: 2019-09-19
Last updated by the study team: 2022-08-23

Who can join

Age: 25 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

females 25 - 65 years of age
minimal to moderate Crow's Feet wrinkles at rest
moderate to severe Crow's Feet on contraction
adequate vision to assess facial wrinkles in a mirror
willingness to refrain from products affecting skin remodeling
female subjects must be not pregnant and non-lactating
subjects should be in good general health

You may not qualify if…

history of adverse reactions to any prior botulinum toxin treatments
history of vaccination or non-response to any prior botulinum toxin treatments
botulinum toxin treatment in the prior 6 months
present or history of neuromuscular disease, eyelid ptosis, muscle weakness, paralysis, or "dry eye"
history of peri-ocular surgery, brow lift or related procedures
procedures affecting the lateral canthal region in the prior 12 months
application of topical prescription medication to the treatment area
female subjects who are pregnant or are nursing a child

Where it is running

Baumann Cosmetic & Research Institute — Miami, Florida, United States
Synexus, Inc. — Pinellas Park, Florida, United States
Forefront Dermatology — Louisville, Kentucky, United States
Westlake Dermatology Clinical Research Center — Austin, Texas, United States
Virginia Clinical Research, Inc. — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.